9-PAHSA-d31 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 µM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-kappaB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease[1][2][3][4].
Molekulargewicht:
570.08
Reinheit:
99.00
Formel:
C34H35D31O4
Target-Kategorie:
CGRP Receptor,Isotope-Labeled Compounds,NF-kappaB
Anwendungsbeschreibung:
MCE Product type: Isotope-Labeled Compounds
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
